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ABSTRACT 
A remarkable property of the machinery 
for import of peroxisomal matrix proteins is that it 
can accept already folded proteins as substrates. 
This import involves binding of newly synthesized 
proteins by cytosolic peroxisomal biogenesis 
factor 5 (PEX5), followed by insertion of the 
PEX5-cargo complex into the peroxisomal 
membrane at the docking/translocation module 
(DTM). However, how these processes occur 
remains largely unknown. Here, we used truncated 
PEX5 molecules to probe the DTM architecture. 
We found that the DTM can accommodate a larger 
number of truncated PEX5 molecules comprising 
amino acid residues 1-197 than full-length PEX5 
molecules. A shorter PEX5 version (PEX5(1-125)) 
still interacted correctly with the DTM; however, 
this species was largely accessible to exogenously 
added proteinase K, suggesting that this protease 
can access the DTM occupied by a small PEX5 
protein. Interestingly, the PEX5(1-125)-DTM 
interaction was inhibited by a polypeptide 
comprising PEX5 residues 138-639. Apparently, 
the DTM can recruit soluble PEX5 through 
interactions with different PEX5 domains 
suggesting that the PEX5-DTM interactions are to 
some degree fuzzy. Finally, we found that the 
interaction between PEX5 and PEX14, a major 
DTM component, is stable at pH 11.5. Thus, there 
is no reason to assume that the hitherto intriguing 
resistance of DTM-bound PEX5 to alkaline 
extraction reflects its direct contact with the 
peroxisomal lipid bilayer. Collectively, these 
results suggest that the DTM is best described as a 
large cavity-forming protein assembly into which 
cytosolic PEX5 can enter to release its cargo. 
 
INTRODUCTION 
 Peroxisomal matrix proteins are encoded 
in nuclear genes, synthesized on cytosolic 
ribosomes and post-translationally targeted to the 
organelle (1) via one of two peroxisomal targeting 
signals (PTS), the PTS type 1 (PTS1), and the PTS 
type 2 (PTS2), respectively. The PTS1 is a small 
C-terminally located peptide frequently ending 
with the sequence SKL present in most 
peroxisomal matrix proteins (2, 3). The PTS2 is a 
degenerated nonapeptide present at the N-termini 
of just a few mammalian proteins (4, 5). The 
machinery that recognizes these proteins and 
promotes their translocation across the peroxisome 
membrane is rather complex. In mammals, it 
comprises at least 10 peroxins plus a few other 
proteins mostly involved in 
ubiquitination/deubiquitination events (reviewed 
in (6)). These components can be grouped into 
four sets. These are: 1) the shuttling receptors 
PEX5 and the PEX5.PEX7 complex, which 
1
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The peroxisomal matrix protein translocon 
recognize PTS1 and PTS2 proteins, respectively 
(7–12); 2) the peroxisomal membrane 
docking/translocation module (DTM) comprising 
PEX13, PEX14 and the three “Really Interesting 
New Gene” (RING) finger peroxins, PEX2, 
PEX10 and PEX12 (13, 14); 3) the receptor export 
module (REM) comprising the two “ATPases-
associated with diverse cellular activities” (AAA), 
the mechanoenzymes PEX1 and PEX6, plus their 
membrane anchor PEX26 (15); and 4) a group of 
soluble proteins involved in 
ubiquitination/deubiquitination of PEX5 (i.e., 
E2D1/2/3 and USP9X; (16–18)) and recognition 
of monoubiquitinated PEX5 by the REM (AWP1; 
(19)). 
According to current models (6, 20–23), 
sorting of proteins to the peroxisomal matrix starts 
with their recognition in the cytosol by the 
shuttling receptors PEX5 or PEX5.PEX7. The 
receptor-cargo complex then interacts with the 
peroxisomal membrane DTM, an event ultimately 
leading to the insertion of the receptor into the 
organelle membrane with the concomitant 
translocation of the cargo into the peroxisome 
matrix (24–27). At this stage PEX5 behaves as a 
transmembrane protein (28). Indeed, biochemical 
experiments have shown that DTM-bound PEX5 
exposes the majority of its mass into the organelle 
matrix whereas a small N-terminal domain of 
approximately 2 kDa remains exposed to the 
cytosolic milieu (29). Interestingly, binding of 
cytosolic cargoes by the corresponding receptors, 
translocation of these cargo proteins across the 
peroxisomal membrane and their release into the 
organelle matrix are all NTP hydrolysis-
independent events (24, 26, 30). Apparently, the 
driving force for peroxisomal protein import relies 
on the strong protein-protein interactions that are 
established between PEX5 on one side and DTM 
components on the other (30, 31). Several short 
linear motifs found at the N-terminal half of PEX5 
(eight in the human protein), the so-called 
pentapeptide motifs (see below), are crucial for the 
PEX5-DTM interaction. All of them interact with 
the N-terminal domain of PEX14 quite strongly 
(dissociation constants in the nanomolar range) 
whereas motifs 2-4 also interact with PEX13  
((32–34); see Fig. 1). 
After cargo release, the receptors are 
recycled back into the cytosol. This is the only part 
of the protein transport cycle that requires energy 
from ATP hydrolysis (30). Extraction of receptors 
from the DTM involves two steps. First, PEX5 is 
monoubiquitinated at a conserved cysteine residue 
(Cys11 in the mammalian protein) (18, 35). 
Subsequently, monoubiquitinated PEX5 (Ub-
PEX5) is extracted back into the cytosol in an 
ATP-dependent manner by the REM, a step that 
also triggers the release of PEX7 from the DTM 
(27, 36, 37). After removal of ubiquitin in the 
cytosol, PEX5 then engages in a new protein 
transport cycle (17, 38, 39). 
A remarkable property of the peroxisomal 
matrix protein import machinery (PIM) is its 
capacity to accept already folded proteins as 
substrates. Actually, in some cases even 
oligomeric proteins can be imported into 
peroxisomes although the import efficiency of this 
type of cargoes is probably low ((40–42); 
reviewed in (43)). How the PIM accomplishes this 
feat while at the same time ensuring that matrix 
proteins are retained in the organelle is currently a 
central question in the field of peroxisome 
biogenesis. Some models have been proposed (see 
“Discussion”) but the data supporting each of 
these different perspectives are still scarce. In this 
work we revisited the hitherto intriguing resistance 
of DTM-bound PEX5 to alkaline extraction, a 
property that has been used to suggest that PEX5 
is a pore-forming protein. In addition, we used an 
established cell-free in vitro system and truncated 
versions of PEX5 to probe the architecture of the 
DTM. Collectively, our results suggest that the 
DTM is conceptually best described as a gated 
large cavity-containing protein assembly in which 
soluble PEX5 enters to release its cargo. 
 
RESULTS 
The PEX5-PEX14 interaction is resistant to 
alkaline pH. 
As stated above, PEX5 acquires a 
transmembrane topology during its transient 
passage through the DTM (29). Strikingly, DTM-
embedded PEX5 cannot be extracted from 
peroxisomes by alkaline (pH 11.5) solutions, a 
property generally attributed to proteins that 
interact directly with the lipid bilayer of biological 
membranes (10, 28, 44, 45). This biochemical 
behavior of peroxisomal PEX5 is intriguing 
because its N-terminal half (the domain necessary 
and sufficient for insertion of the receptor into the 
peroxisome membrane) lacks phylogenetically 
2
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The peroxisomal matrix protein translocon 
conserved hydrophobic or amphipathic regions 
that might support a direct contact of the protein 
with the lipid bilayer of the peroxisomal 
membrane (25, 46, 47). Actually, a recombinant 
protein comprising this PEX5 domain alone is 
highly soluble and shows no tendency to 
precipitate or aggregate even upon boiling, a 
property that stems from its intrinsically 
disordered nature (48). Despite this inconsistency, 
the striking alkaline resistance of peroxisomal 
PEX5 has led some authors to propose that PEX5 
may function as a pore-forming protein ((49, 50); 
see also “Discussion”). There is, however, a 
simpler explanation for the peculiar biochemical 
behavior of peroxisomal PEX5 – the protein-
protein interactions involving PEX5 and DTM 
components may be alkaline pH-resistant. We 
decided to test this possibility. 
There are only two DTM components 
known to interact with the N-terminal half of 
PEX5. These are PEX13 and PEX14 (32–34, 51, 
52), respectively. The PEX13-PEX5 interaction is 
rather weak and actually difficult to capture in in 
vitro binding assays (33, 53–55). PEX14, by 
contrast, interacts very strongly with PEX5 (13, 
14, 52, 56). The main interaction involves the first 
80 amino acid residues of PEX14, a domain that is 
probably embedded in the peroxisomal membrane 
or even exposed into the organelle matrix, and any 
of the eight pentapeptide motifs present in the N-
terminal half of PEX5 (32, 52, 56–59). We 
focused on the latter interaction. 
Two strategies were used to assess 
whether or not the PEX5-PEX14 interaction is 
alkaline pH-resistant. In the first, we subjected 
recombinant PEX5, a protein comprising the first 
80 amino acid residues of PEX14 (hereafter 
referred to as NDPEX14) and a mixture of both 
proteins to pH 11.5 polyacrylamide gel 
electrophoresis. The results in Fig. 2A show that 
indeed this protein interaction is stable at pH 11.5. 
In the second strategy, we subjected the same 
recombinant proteins to size-exclusion 
chromatography performed in the presence of 0.1 
M sodium carbonate, the solution generally used 
to extract biological membranes. As shown in Fig. 
2B, protein complexes between PEX5 and 
NDPEX14 were easily detected. 
Thus, there is no need to assume that the 
resistance of peroxisomal PEX5 to alkaline 
extraction reflects an interaction of the protein 
with the lipid bilayer of the organelle – the 
properties of the PEX5-PEX14 interaction fully 
explain the striking biochemical behavior of 
DTM-embedded PEX5. 
 
The DTM can accommodate more molecules of 
a truncated PEX5 species than full-length 
PEX5. 
The very low abundance of PEX5 and 
DTM components, even in peroxisome-rich cells, 
together with the lability of detergent-solubilized 
PEX5-DTM complex during standard biochemical 
procedures have greatly hampered a structural 
characterization of the peroxisomal protein 
translocon (13, 14). There are, nevertheless, 
indirect approaches, such as in vitro binding 
analyses that can provide valuable data on the 
architecture/mechanism of protein complexes (60). 
We applied such a strategy to the PEX5-DTM 
complex. 
We first asked whether or not C-terminally 
truncated PEX5 molecules can interact with the 
peroxisomal membrane at the same stoichiometry 
of full-length PEX5. For this purpose, we used an 
established post-nuclear supernatant (PNS)-based 
in vitro system programmed with in vitro 
synthesized 
35
S-labeled PEX5 proteins and 
assessed insertion of the different PEX5 species 
into the peroxisome membrane by treating 
organelle suspensions with proteinase K (PK) (29, 
61). This assay explores the fact that soluble PEX5 
is extremely sensitive to proteolysis due to the 
natively unfolded nature of its N-terminal half, 
whereas PEX5 inserted at the DTM is resistant to 
PK (29, 48). Two populations of DTM-embedded 
PEX5 can be discerned after protease treatment. 
These are the so-called stage 2 and stage 3 PEX5 
(29, 35). Stage 2 PEX5 corresponds to non-
ubiquitinated PEX5; this species is clipped by PK 
losing a domain of ~2 kDa from its N-terminus. 
Stage 3 PEX5 is completely resistant to the 
protease and represents monoubiquitinated PEX5. 
Besides full-length PEX5 possessing an alanine 
instead of a cysteine at position 11 (PEX5(C11A); 
see below), two other in vitro synthesized 
35
S-
labeled PEX5 proteins were used in these initial 
experiments, namely, PEX5(1-324;C11A), and 
PEX5(1-197;C11A), comprising amino acid 
residues 1-324 and 1-197 of PEX5, respectively 
(see Fig. 1). Once at the DTM, these C11A 
mutants cannot be monoubiquitinated and 
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The peroxisomal matrix protein translocon 
exported (38), a property that should allow us to 
reach saturation of PEX5-binding sites at the 
peroxisome membrane more easily. For practical 
reasons (see “Experimental Procedures”), these 
proteins were synthesized in vitro from pET-28-
based plasmids. Thus, they all contain a histidine 
tag at their N-termini (see Fig. S1A). The in vitro 
assays were performed at 37 °C, in the presence of 
ATP, conditions that lead to the export of 
endogenous rat PEX5 from the peroxisome and to 
a very low occupation of DTMs by this functional 
PEX5 species (see Fig. S2). 
As shown in Fig. 3, we were able to reach 
saturation or near-saturation conditions for many 
of the PK-resistant species detected in these assays 
(A and B, upper panels). Interestingly, both 
protease-protected PEX5(1-324;C11A) and 
PEX5(1-197;C11A) displayed an unexpected 
heterogeneity in these experiments. Indeed, in 
addition to a set of partially cleaved species, a 
protein band corresponding to intact radiolabeled 
protein was also detected, particularly in the 
PEX5(1-197;C11A) assays (indicated with 
brackets and arrow heads, respectively, in Fig. 3A 
and B). 
The partially cleaved species represent 
membrane-embedded molecules exposing their N-
termini into the cytosol, i.e., at the stage 2 level, as 
determined by digesting the radiolabeled proteins 
with Genenase I (29). Genenase I is an engineered 
subtilisin from Bacillus amyloliquefaciens (62) 
that cleaves PEX5 near its N-terminus, 
immediately after Phe24 ((29); see Fig. S3 and 
S4). As shown in Fig. 4A, Genenase I converted 
all PK-resistant PEX5(1-197;C11A) species into a 
single 31-kDa protein, which co-migrates with the 
smallest PEX5(1-197;C11A) fragment generated 
by PK. 
The heterogeneity of the PK-cleaved 
PEX5 species detected in these experiments, 
together with the distribution of methionine 
residues at the N-terminus of PEX5, raises some 
uncertainty in the calculation of relative molar 
ratios (see Fig. S1). Thus, three different 
possibilities for the distribution of PK-cleavage 
sites in the N-termini of PEX5 truncated species 
were considered (see Fig. S1F for details). The 
data from the most likely possibility (scenario #1; 
see Fig. S1F) are shown in Fig. 3A and B (lower 
panels). The results suggest that, at saturation, the 
approximate ratios of PEX5-binding sites in 
peroxisomes for PEX5(1-197;C11A), PEX5(1-
324;C11A), and PEX5(C11A) are 2.5:1.2:1, 
respectively. In the other two possibilities the PK-
cleavage sites were assumed to be at positions 
leading to the largest (scenario #2) and smallest 
(scenario #3) PEX5(1-197;C11A):PEX5(1-
324;C11A):PEX5(C11A) ratios, respectively – 
values of 3.2:1.4:1 and 1.8:1:1 were obtained for 
each of these scenarios (see Fig. S1F). Thus, 
regardless of the actual location of PK-cleavage 
sites in the N-termini of PEX5 truncated species, it 
is clear that peroxisomes can accommodate more 
PEX5(1-197;C11A) molecules than full-length 
PEX5. Actually, these ratios are probably larger, 
particularly for PEX5(1-197;C11A), because PK-
resistant intact PEX5(1-197;C11A) is also 
specifically bound to peroxisomes, as shown 
below. 
The finding that a non-ubiquitinatable 
PEX5 species can acquire an organelle-associated 
status remaining completely resistant to PK was 
particularly striking because up to now the only 
PEX5 species known to display this behavior was 
DTM-embedded Ub-PEX5. Due to the potential 
mechanistic implications of this finding we 
analyzed the properties of this species in detail. 
Considering that unusual large amounts of 
radiolabeled proteins were used in these assays 
(see “Experimental Procedures”), we first 
addressed the possibility that intact protease-
resistant PEX5(1-197;C11A) might result from 
some non-specific event (e.g., encapsulation of a 
small fraction of the radiolabeled protein into 
some membrane vesicles during sample 
processing). However, we found that this species 
co-purifies with peroxisomes upon gradient 
centrifugation, as does stage 2 PEX5(1-197;C11A) 
(Fig. 4B). Also, similarly to stage 2 species, intact 
protease-resistant PEX5(1-197;C11A) cannot be 
extracted from the peroxisomal membrane by 
sonication in a low ionic-strength buffer, 
conditions that lead to the release of catalase, a 
peroxisomal matrix protein (Fig. 4C). Thus, intact 
protease-resistant PEX5(1-197;C11A) represents a 
peroxisome membrane-bound species. 
Furthermore, its insertion into the organelle 
membrane is blocked when the in vitro assays are 
performed in the presence of NDPEX14 (Fig. 4D). 
As stated above, NDPEX14 binds strongly to the 
pentapeptide motifs present in PEX5 (33, 52, 56), 
thus blocking insertion of the shuttling receptor 
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The peroxisomal matrix protein translocon 
into the peroxisome membrane (24, 61). 
Importantly, the amount of protease-resistant 
intact PEX5(1-197;C11A) is largely decreased 
when the in vitro assays are performed in the 
presence of recombinant (full-length) 
PEX5(C11A) (Fig. 5A, compare lanes 4 and 5), 
and, conversely, recombinant PEX5(1-197;C11A) 
blocks insertion of radiolabeled PEX5(C11A) into 
the peroxisome membrane (Fig. 5A, compare 
lanes 7 and 8). Thus, both truncated and full-
length PEX5 species compete for the same PEX5-
binding sites at the peroxisome membrane. 
The presence of a histidine tag at the N-
terminus of PEX5(C11A) does not change its 
behavior upon PK treatment – as shown in Fig. 3, 
essentially all protease-protected PEX5(C11A) is 
clipped by the protease into a slightly shorter 
protein, as previously observed for untagged 
PEX5 (e.g., see Fig. 1 in (35)). Nevertheless, 
aiming at better understanding the nature of PK-
resistant intact PEX5(1-197;C11A), we still 
considered that this might not be so for truncated 
PEX5 species. Thus, we performed an in vitro 
assay using a large volume of a rabbit reticulocyte 
lysate (RRL) containing an untagged version of 
PEX5(1-197;C11A). As shown in Fig. 5B, similar 
abnormal protease-resistant species were detected 
with this radiolabeled protein as well. Apparently, 
intact PK-resistant species are generated when 
large amounts of truncated PEX5 molecules are 
used in these assays. 
Finally, we analyzed the import kinetics of 
intact PK-resistant PEX5(1-197;C11A). The 
results in Fig. 5C suggest that this species displays 
a slower kinetics than partially accessible PK-
resistant PEX5 species. Seemingly, the 
peroxisomal PEX5-binding site occupied by this 
abnormal PEX5 population is kinetically distinct 
from the one occupied by the partially protease-
accessible species, as the saturation-binding 
experiments shown in Fig. 3B might already 
suggest. 
In summary, the data above suggest that 
PEX5(1-197;C11A) and PEX5(C11A) bind to the 
same sites at the peroxisome membrane. However, 
they do so with different stoichiometries. 
Apparently, many of the sites available to bind a 
full-length PEX5(C11A) molecule can 
accommodate more than one PEX5(1-197;C11A) 
molecule. 
 
DTM-bound PEX5(1-125;C11A/K) is accessible 
to PK. 
In addition to PEX5(1-197;C11A) and 
PEX5(1-324;C11A), one other C-terminally 
truncated species comprising just the first 125 
amino acid residues of PEX5 (PEX5(1-
125;C11A)) was characterized in this work. Our 
initial aim was to use this protein in the saturation-
binding experiments described above, and 
determine whether the DTM could accommodate 
an even larger number of a smaller PEX5 species. 
However, this turned out to be not possible 
because PEX5(1-125;C11A) is mostly accessible 
to PK in the in vitro assays (Fig. 6A, compare 
lanes 3 and 4 with lanes 7 and 8). Strikingly, when 
a ubiquitinable version of this protein, PEX5(1-
125;C11K), possessing a lysine at position 11 was 
used in in vitro assays supplemented with AMP-
PNP (conditions that allow monoubiquitination of 
PEX5 at the peroxisome but not its export by the 
REM; (17)), a monoubiquitinated species was 
clearly detected (Fig. 6A, lane 5; see also Fig. S5). 
Interestingly, and similarly to PEX5(1-125;C11A), 
this monoubiquitinated species (Ub-PEX5(1-
125;C11K)) is also accessible to PK (Fig. 6A, 
compare lanes 1 and 2 with lanes 5 and 6). 
Interaction of PEX5 with the peroxisomal 
DTM occurs in two steps: 1) a reversible docking 
event, in which PEX5 remains protease-accessible 
(24), and 2) insertion of PEX5 into the DTM, an 
essentially irreversible step (in the absence of 
ATP) that yields protease-resistant PEX5 (29). 
Given the results described above for PEX5(1-
125;C11A/K), we hypothesized that this protein 
might be unable to enter the DTM remaining 
trapped at the docking step and thus protease-
accessible. To test this, organelles from an in vitro 
assay programmed with radiolabeled PEX5(1-
125;C11K) and performed in the presence of 
AMP-PNP were resuspended in import buffer and 
incubated with a vast excess of recombinant 
PEX5(1-324), which competes with PEX5 at the 
docking step (24), or PEX19, a protein involved in 
a different aspect of peroxisome biogenesis and 
used here as a negative control (63). After 
centrifugation, to separate organelle-associated 
proteins from soluble ones, samples were analyzed 
by SDS-PAGE/autoradiography. Note that since 
no protease-treatment step can be included in these 
assays, radiolabeled protein non-specifically 
adsorbed to the organelles is not destroyed, thus 
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The peroxisomal matrix protein translocon 
explaining the relatively large background 
observed in this type of experiments (see (24)). 
Despite this limitation, the results in Fig. 6B show 
that a considerable amount of unmodified 
PEX5(1-125;C11K) was specifically extracted 
from the organelles upon incubation with 
recombinant PEX5(1-324), as expected for a 
PEX5 species at the docking step (24). By 
contrast, essentially all Ub-PEX5(1-125;C11K) 
remained in the organelle pellet. Seemingly, Ub-
PEX5(1-125;C11K) is beyond the docking step. 
Data showing that Ub-PEX5(1-125;C11K) 
is actually upstream of the export step were 
obtained in a two-step import-export experiment 
(17). Briefly, an organelle pellet from an in vitro 
assay programmed with radiolabeled PEX5(1-
125;C11K) and performed in the presence of 
AMP-PNP (to accumulate Ub-PEX5(1-125;C11K) 
at the DTM) was resuspended in import buffer and 
incubated in the presence of either AMP-PNP (to 
maintain the block of the REM) or ATP (to 
activate the REM). Organelle-bound and soluble 
proteins were then analyzed by SDS-
PAGE/autoradiography. As shown in Fig. 6C 
(right panel), no Ub-PEX5(1-125;C11K) was 
released into the supernatant in the reaction 
containing AMP-PNP, as expected. In contrast, a 
large fraction of Ub-PEX5(1-125;C11K) was 
found in the supernatant from the ATP-containing 
export reaction. Exactly the same results were 
obtained with PEX5(1-197;C11K), used in this 
assay as a positive control (Fig. 6C, left panel). 
Thus, Ub-PEX5(1-125;C11K) is a substrate for the 
REM. 
Finally, to better characterize PEX5(1-
125;C11K), we asked if a portion of its 
polypeptide chain becomes exposed into the 
peroxisomal matrix during its passage through the 
DTM. For this, we adapted an experimental 
strategy previously used to show that a portion of 
the polypeptide chains of PEX5 and PEX7 reach 
the peroxisome matrix (27, 64). Specifically, we 
produced two almost identical PEX5(1-125;C11K) 
proteins both having at their C-termini an 
extension of about 5 kDa. In one of these proteins, 
named PEX5(1-125;C11K)-clv, the extension 
comprises a cleavable but otherwise non-
functional PTS2 derived from pre-thiolase pre-
sequence (64), followed by 19 amino acid residues 
corresponding to the N-terminus of human sterol 
carrier protein-2; the second protein, PEX5(1-
125;C11K)-nclv, is virtually identical to PEX5(1-
125;C11K)-clv with the exception that it lacks the 
last two residues of the non-functional pre-thiolase 
pre-sequence. This deletion was designed based on 
previous work showing that a similar deletion in 
pre-phytanoyl CoA hydroxylase dramatically 
decreased its processing efficiency at the 
peroxisomal matrix (65). Thus, if the C-terminus 
of PEX5(1-125;C11K)-clv becomes exposed into 
the peroxisomal matrix, a 2-kDa shorter protein 
should be generated by the action of Tysnd1, the 
peroxisomal matrix protease that processes PTS2-
containing proteins (66), whereas no or very little 
cleavage should be observed for PEX5(1-
125;C11K)-nclv. The results of an in vitro assay 
performed with these two proteins revealed 
precisely this behavior, although the fraction of 
cleaved PEX5(1-125;C11K)-clv is relatively small 
(Fig. 6D). We conclude that at least a fraction of 
PEX5(1-125;C11K)-clv acquires a transmembrane 
topology during its transient passage through the 
DTM. 
 Taken together the data shown in Fig. 6 
suggest that a small protein comprising just the 
first 125 amino acid residues of PEX5 can enter 
the DTM, yielding a correct substrate for the 
RING-finger peroxins and to the REM, and yet 
remain largely accessible to PK added from the 
cytosolic side of the peroxisomal membrane. 
 
Two non-overlapping PEX5 fragments can 
interact with the DTM in a competitive 
manner. 
 We have previously shown that a 
truncated PEX5 lacking the first 110 amino acid 
residues of the receptor can still become inserted 
into the DTM in a cargo-dependent manner (67). 
In this work, larger N-terminal truncations were 
characterized. The aim was to obtain a functional 
N-terminal truncated PEX5 species displaying no 
sequence overlap with PEX5(1-125) so that we 
could better understand the architecture/function 
of the DTM. 
 We found that truncating the first 137 
amino acid residues of PEX5 resulted in a species 
(PEX5(N137)) that is still active in the in vitro 
assays, as demonstrated by the acquisition of an 
organelle-associated, protease-protected status in a 
cargo-dependent manner (see Fig. 7A). No import 
capacity was observed for a slightly shorter 
6
 at U
N
IV
ERSID
A
D
E D
O
 PO
RTO
 on N
ovem
ber 2, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
The peroxisomal matrix protein translocon 
protein lacking amino acid residues 1-148 (data 
not shown). 
We then used recombinant PEX5(N137) 
in competition experiments in the PNS-based in 
vitro assays. As might be expected for two 
proteins that share some of their DTM-interacting 
regions (see Fig. 1), recombinant PEX5(N137) 
competes with PEX5(1-197;C11K) for insertion 
into the DTM, as shown by the large decrease in 
the amount of monoubiquitinated PEX5(1-
197;C11K) in organelle pellets (Fig. 7B, lanes 1-
3). Importantly, the same result was observed for 
PEX5(1-125;C11K) (Fig. 7B, lanes 4-6). 
Competition between PEX5(N137) and 
PEX5(1-125;C11K) could occur at the docking 
step or only at the insertion step. To clarify this we 
repeated the experiment presented in Fig. 6B but 
this time using recombinant PEX5(N137) as a 
competitor of organelle-associated PEX5(1-
125;C11K). The results in Fig. 7C suggest that 
PEX5(N137) competes with PEX5(1-125;C11K) 
at the docking step. 
 
DISCUSSION 
Protein translocons with the capacity to 
accept already folded proteins as substrates are not 
unique to peroxisomes. Indeed, several other 
protein transport systems found in both eukaryotes 
and prokaryotes have this ability. These include 
the nuclear import/export machinery, the 
chloroplast and bacterial twin-arginine 
translocators, a vast number of bacterial protein 
secretion machineries such as the type II, type IV 
and some type V secretion systems, and pore-
forming proteins of both prokaryotic and 
eukaryotic origin (68–73). Although the diversity 
of architectures and compositions of these 
machineries is overwhelming, they can be coarsely 
grouped into three mechanistic classes: 1) those 
that comprise membrane proteins with the capacity 
to transiently assemble into a “custom”-size 
transmembrane pore every time a cargo has to be 
transported (i.e., the twin-arginine translocator); 2) 
those built of proteins that are initially soluble but 
which undergo oligomerization and major 
conformational changes enabling them to insert 
into a membrane creating pores of variable 
dimensions (pore-forming proteins/toxins), and 3) 
those that comprise a gated pore of fixed geometry 
and composition through which folded and soluble 
cargoes are transported  (e.g., the nuclear pore 
complex and the bacterial type II and IV secretion 
systems) (68–73). Which of these three 
mechanisms, if any, best describes the PIM has 
been a major question in the field. 
We have previously proposed that newly 
synthesized folded peroxisomal matrix proteins 
are translocated across the organelle membrane by 
PEX5 itself, when the soluble receptor interacts 
with and becomes inserted into the DTM (29, 31). 
It is explicitly assumed in this model that soluble 
cargo-loaded-PEX5 is recruited into a 
proteinaceous pore/channel formed by DTM 
components. The transmembrane topology of 
DTM-embedded PEX5 (29), the absence of any 
obvious phylogenetically conserved hydrophobic 
or amphipathic domains in PEX5,  the fact that the 
DTM-interacting domain of PEX5 (i.e., its N-
terminal half) is a natively unfolded domain that 
remains in solution even upon boiling (48), and 
the membrane topology of PEX14, which has its 
strongest PEX5-interacting domain embedded in 
the peroxisomal membrane or even exposed into 
the organelle matrix (59), are some of the facts 
supporting this idea (see also (47)). The resistance 
of DTM-embedded PEX5 to alkaline extraction, 
although striking, has been interpreted within the 
context of all the other PEX5 data, as probably 
meaning that there is some unusually strong 
protein-protein interaction involving PEX5 on one 
side and members of the DTM on the other (28, 
44, 45, 47). 
A different perspective is adopted in the 
so-called transient pore model (49), which uses the 
alkaline-resistance of peroxisomal PEX5 as its 
main supporting fact. We note that in its essence 
the transient pore model is a derivative of the one 
described above, i.e., it also proposes that 
cytosolic cargo proteins are pushed across the 
organelle membrane by PEX5 itself, when the 
receptor interacts with the DTM. The novelty of 
that model is the idea that PEX5 becomes 
integrated into the lipid bilayer of the peroxisomal 
membrane, thus acting as a pore-forming toxin-
like protein (49, 74). The data in this work provide 
a much simpler explanation for the alkaline-
resistance of DTM-embedded PEX5 and therefore 
reconcile the discrepancies between the 
biochemical properties of peroxisomal PEX5, and 
the primary structure and biochemical behavior of 
its N-terminal half, which were never fully 
explained by the transient pore model. Clearly, 
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The peroxisomal matrix protein translocon 
there is no need to assume that PEX5 is a pore-
forming toxin-like protein because the resistance 
of its peroxisomal pool to alkaline extraction can 
now be explained by the properties of the PEX5-
PEX14 interaction. 
Although additional biochemical work and 
detailed structural data will be necessary to 
understand how the PIM transports newly 
synthesized proteins across the organelle 
membrane, the data presented here for the PEX5 
truncated species can be used to infer some of its 
properties (see Fig. 8). 
The finding that the DTM can 
accommodate more molecules of PEX5(1-
197;C11A) than full-length PEX5 is particularly 
interesting. First, it suggests that each site at the 
DTM available to bind a single full-length PEX5 
molecule contains more than one PEX5-
interacting domain. Second, since several PEX5(1-
197;C11A) molecules can enter into a single DTM 
site, at least some of these PEX5-interacting 
domains are probably equivalent, i.e., they can 
bind to the same PEX5 sequence(s). We tried to 
extend these findings by using an even smaller 
PEX5 protein, PEX5(1-125;C11A/K), harboring 
just two pentapeptide motifs, in our in vitro 
import/export assays. Our hypothesis was that at 
saturating conditions an even larger number of 
PEX5(1-125) molecules should be found at the 
DTM. However, this turned out not to be possible 
because PEX5(1-125;C11A/K) is inefficient in 
these in vitro assays (e.g., see Fig. 6A), and, more 
importantly, peroxisome associated PEX5(1-
125;C11A/K) is largely accessible to PK. Despite 
this limitation, several conclusions can be drawn 
from the PEX5(1-125;C11K) data. First, despite 
representing just 1/5 of full-length PEX5, PEX5(1-
125;C11K) is still correctly monoubiquitinated at 
the DTM and exported by the REM. Clearly, 
amino acid residues 126-639 of PEX5 convey no 
essential information to the ubiquitination/export 
components of the PIM. Another interesting 
property of PEX5(1-125;C11K) regards the fact 
that its entry into the DTM can be competed by 
PEX5(N137). We do not know presently whether 
this competition is due to steric hindrance or if the 
two proteins bind the same DTM component(s) 
but, regardless, the fact that two non-overlapping 
PEX5 fragments can enter into the DTM suggests 
that this membrane complex can engage into 
interactions with PEX5 using different binding 
paths. In other words, it is possible that the first set 
of interactions that are established between a 
single PEX5 molecule and the DTM during the 
docking/insertion steps, most of them likely 
involving PEX14 (75, 76), do not occur 
necessarily through a pre-defined order of events. 
If true, this would suggest that at least some of the 
PEX5-DTM interactions are polymorphic in 
nature, and probably better described by the 
principles that rule fuzzy protein-protein 
interactions (see (77, 78)). The data discussed 
above for PEX5(1-197), the fact that the N-
terminal half of PEX5 is a natively unfolded 
domain interacting with DTM components mainly 
(if not exclusively) through several small motifs, 
together with an abundance of intrinsic disorder in 
many DTM components (e.g., 40% and 60% of 
human PEX13 and PEX14 sequences, 
respectively, are predicted to be intrinsically 
disordered by the PONDR-VLXT algorithm (79, 
80); Molecular Kinetics, Inc.) are surely 
compatible with this idea. 
Finally, the fact that PEX5(1-125;C11K) 
enters into the DTM, where it is 
monoubiquitinated yielding the correct substrate 
for the REM, and yet remains accessible to PK 
added from the cytosolic side of the peroxisomal 
membrane is also interesting. In principle, this 
could simply suggest that PEX5(1-125;C11K) 
remains trapped at the docking step and that 
docking at the DTM would already be sufficient to 
position this PEX5 fragment in the correct 
orientation to be monoubiquitinated at the DTM 
and exported by the REM. However, we found 
that the interaction of Ub-PEX5(1-125;C11K) 
with the DTM, in contrast to the PEX5-DTM 
interaction at the docking step, is essentially 
irreversible. Furthermore, the data shown in Fig. 
6D suggest that the C-terminus of at least a 
fraction of PEX5(1-125;C11K)-clv reaches the 
matrix side of the peroxisome membrane. Thus, it 
is more likely that PEX5(1-125;C11A/K) becomes 
inserted into the DTM, as all the other PEX5 
proteins used in this work do, but that due to its 
small size there is still sufficient space inside the 
DTM to provide access to PK. 
Altogether, the data presented in this work 
reveal novel aspects of the PEX5-DTM interaction 
and provide additional evidence to support the 
idea that the DTM comprises the transmembrane 
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The peroxisomal matrix protein translocon 
hydrophilic channel in which PEX5 enters to 
deliver its cargoes into the peroxisome matrix. 
 
EXPERIMENTAL PROCEDURES 
 
Plasmids – The oligonucleotides used to generate 
the plasmids described below are listed in Table 
S1. The cDNA encoding the large isoform of 
human PEX5 ((10), hereafter referred to as PEX5) 
was obtained by PCR amplification of the plasmid 
pQE-30-PEX5 (53) and cloned into the NdeI/SalI 
restriction sites of pET-28c (Novagen), originating 
pET-28-PEX5. To generate the plasmid encoding 
full-length PEX5 possessing an alanine instead of 
a cysteine at position 11, the 0.3 kb NcoI/SdaI 
fragment of pET-28-PEX5(1-324;C11A)   (27) 
was inserted into NcoI/SdaI-digested pET-28-
PEX5, originating pET-28-PEX5(C11A). The 
cDNAs encoding the first 125 and 197 amino acid 
residues of PEX5 possessing an alanine at position 
11 were obtained by PCR amplification of the 
plasmid pET-28-PEX5(1-324;C11A)  and cloned 
into the NdeI/HindIII, and XbaI/HindIII sites of 
pET-28a vector (Novagen), originating plasmids 
pET-28-PEX5(1-125;C11A) and pET-28-PEX5(1-
197;C11A), respectively. The plasmid encoding 
the first 324 amino acid residues of PEX5 
possessing a lysine at position 11 (pET-28-
PEX5(1-324;C11K)) was obtained with the 
QuikChange® site-directed mutagenesis kit 
(Agilent Technologies), using pET-28-PEX5(1-
324) as template (16) and the primers described 
elsewhere (38). To generate plasmids encoding the 
first 125 and 197 amino acid residues of PEX5 
possessing a lysine at position 11, the EcoRV/SdaI 
1.5 kb fragment of pET-28-PEX5(1-324;C11K) 
was inserted into EcoRV/SdaI-digested pET-28-
PEX5(1-125;C11A) and pET-28-PEX5(1-
197;C11A), originating plasmids pET-28-PEX5(1-
125;C11K) and pET-28-PEX5(1-197;C11K) 
respectively. The cDNA encoding amino acids 
138 to 639 of PEX5 (PEX5(ΔN137)) was obtained 
by PCR amplification from the plasmid pGEM4-
PEX5(C11K) (38) and cloned into the NdeI/SalI 
restriction sites of pET-23a (Novagen), originating 
pET-23-PEX5(ΔN137). The NdeI/SalI insert of 
this plasmid was then cloned into the NdeI/SalI 
sites of pET-28a; this plasmid was then digested 
with NdeI, dephosphorylated with calf intestine 
phosphatase (New England BioLabs) and ligated 
to an adapter encoding the recognition sequence of 
the TEV (Tobacco Etch Virus) protease, 
originating pET-28-TEV-PEX5(ΔN137). A 
synthetic gene encoding a fusion protein 
comprising the first 125 amino acids of human 
PEX5 with the C11K mutation and possessing at 
its C-terminus the polypeptide 
MQRRQVVLGHLRGPADSGWMPQAAPC*LS
GAGFPEAASSFRTHQVSAAPT was codon 
optimized for expression in RRL, synthesized and 
cloned into the NdeI/BamHI sites of pET-28a by 
Genscript. The resultant plasmid, pET-28-
PEX5(1-125;C11K)-clv, encodes the N-terminally 
histidine-tagged PEX5(1-125;C11K) protein fused 
to amino acid residues 1-30 of human pre-thiolase 
harboring the L4R mutation, which abolishes its 
PTS2 function (64), followed by the first 19 
residues of the human sterol carrier protein-2 
precursor (italic). The cleavage site for the 
peroxisomal matrix protease Tysnd1 is marked 
with an asterisk (4, 66). A nearly identical 
plasmid, encoding a fusion protein lacking the -2 
and -1 residues of the Tysnd1 cleavage site (Pro25 
and Cys26, numbering of full-length human pre-
thiolase, underlined in sequence above) was 
constructed in the exact same way, yielding pET-
28-PEX5(1-125;C11K)-nclv. For simplicity the 
two proteins encoded by these plasmids are 
referred to as PEX5(1-125;C11K)-clv and 
PEX5(1-125;C11K)-nclv, respectively. 
 
Expression and purification of recombinant 
proteins – Recombinant histidine-tagged PEX5, 
PEX5(C11A) and PEX5(ΔN137) (53), a protein 
comprising amino acid residues 315-639 of PEX5 
(referred to as TPRs; (48)), and TPRs containing 
the missense mutation N526K (TPRs(N526K), 
numbering of full-length PEX5 (81)), NDPEX14 
(48), PEX19 (82), glutathione S-transferase-
ubiquitin fusion protein (35), PEX5(1-324) and 
PEX5(1-197;C11A) (61) were purified as 
described before. The N-terminal histidine tag of 
PEX5(ΔN137) was removed using histidine-
tagged TEV (Tobacco Etch Virus) protease in 50 
mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM 
EDTA-NaOH, pH 8.0, 1 mM DTT, overnight at 4 
o
C. The protein solution was then incubated with 
HIS-Select Nickel Affinity Gel beads (Sigma) for 
2 hours at 4 
o
C, and PEX5(ΔN137) was recovered 
in the non-bound fraction. The protein was 
concentrated by repeated centrifugation using 
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The peroxisomal matrix protein translocon 
Vivaspin® 2 Sample concentrators, as described 
before (61). 
 
PAGE at pH 11.5 – Recombinant PEX5 (2 µg), 
NDPEX14 (5 µg), and a mixture of both proteins, 
were incubated for 15 min at 23 
o
C in a final 
volume of 2 μL. After dilution with 8 μL of 25 
mM phosphate buffer, pH 11.5, 2.5 mM DTT, 
18% (w/v) glycerol, 0.05% (w/v) bromophenol 
blue, the samples were loaded onto a 9% 
polyacrylamide gel (16.5 cm x 14.5 cm x 0.75 
mm) made in 50 mM Na2HPO4, pH 11.5 with 5 M 
KOH. The gel was run in the same pH 11.5 buffer 
at 4 °C for 5 h 30 m, with power limited to 3 W. 
Proteins were transferred onto a nitrocellulose 
membrane and stained with Ponceau S. Proteins 
were eluted from the membrane by incubating the 
excised bands in SDS-PAGE sample buffer, as 
previously described (83). 
 
Size-exclusion chromatography (SEC) – 
Recombinant PEX5 (180 µg), NDPEX14 (300 µg) 
and a mixture of both proteins, were incubated in 
50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM 
EDTA-NaOH, pH 8.0, 1 mM DTT (50 μL final 
volume) for 15 min at 23 
o
C. Samples were then 
diluted with 200 μL of 0.15 M Na2CO3 (pH after 
dilution = 10.9), incubated on ice for 30 min, and a 
200 µL aliquot was injected into a Superose
TM
 12 
10/300 GL column running with 0.12 M Na2CO3, 
0.5 mM DTT (pH 11.6), at 4 
o
C, and at a flow rate 
of 0.5 mL/min. Fractions of 0.5 mL were collected 
and 30 μL-aliquots were analyzed by SDS-
PAGE/Coomassie blue staining. 
 
Post-nuclear supernatant (PNS)-based in vitro 
assays – Liver PNS was prepared from overnight-
fasted Wistar Han male rats with 6 to 10 weeks of 
age, as described in (61). PNS-based in vitro 
reactions were performed as recently described 
(61), using 600 μg of total PNS protein and 0.1 to 
16 μL of RRL containing the indicated 35S-labeled 
protein per 100-μL of reaction volume in import 
buffer (0.25 M sucrose, 20 mM MOPS-KOH, pH 
7.2, 50 mM KCl, 3 mM MgCl2, 2 μg/mL E-64, 96 
μg/mL methionine). Reactions were typically 
supplemented with 2 mM reduced L-glutathione, 
10 μM bovine ubiquitin and 5 mM ATP or 5 mM 
AMP-PNP. In the latter situation, the PNS was 
first primed for import by incubating 5 min at 37 
ºC in the presence of 0.3 mM ATP. Ubiquitin 
aldehyde was used at a 1 μM final concentration. 
Unless otherwise indicated, in vitro reactions were 
incubated for 45 min at 37 ºC, and treated with 
400 μg/mL (final concentration) of proteinase K 
(PK) for 40 min on ice followed by PK 
inactivation with 500 μg/mL (final concentration) 
of PMSF. Organelles were then processed for 
SDS-PAGE as described (61). In most 
experiments, gels were blotted onto a 
nitrocellulose membrane (GE Healthcare) for 
autoradiography. For quantitative 
autoradiography, the gels were instead stained 
with 0.2% (w/v) Coomassie, 50% (v/v) methanol, 
and 10% (v/v) glacial acetic acid, dried for 2 hours 
at 80 ºC, and exposed to a storage phosphor 
screen. In the two-step in vitro import/export 
assays, radiolabeled proteins were first incubated 
with the primed PNS for 30 min at 37 ºC in the 
presence of AMP-PNP. The reactions were then 
diluted to 1 mL with SEMK buffer (0.25 M 
sucrose, 80 mM KCl, 20 mM MOPS-KOH, pH 
7.2, 1 mM EDTA-NaOH, pH 8.0) and the 
organelles isolated by centrifugation at 11300 g 
for 15 min at 4 
o
C. The organelles were 
resuspended in import buffer and incubated in the 
presence of either 5 mM ATP or 5 mM AMP-PNP 
for 15 min at 37 
o
C. The organelle suspensions 
were then diluted to 1 mL with SEMK buffer and 
centrifuged again at 11300 g for 15 min at 4 
o
C. 
Organelle and soluble fractions were analyzed by 
SDS-PAGE/western-blotting/autoradiography. 
 
Digestion with Genenase I – PK-treated 
organelles from an in vitro assay programmed 
with 
35
S-labeled PEX5(1-197;C11A) or 0.25 µL of 
the RRL containing 
35
S-labeled PEX5(1-
197;C11A) were digested with 2 μg of Genenase I 
(New England BioLabs;(62)), for 30 min at 23 ºC 
in a buffer containing 0.25 M sucrose, 20 mM 
Tris-HCl, pH 8.0, 100 mM NaCl, 1% (w/v) Triton 
X-100, 1 mM EDTA-NaOH, pH 8.0, 1 mM DTT, 
50 μg/mL PMSF, and 1:300 (v/v) mammalian 
protease inhibitor mixture (Sigma). For mass 
spectrometry analyses, 1 μg of recombinant 
PEX5(1-197;C11A) in 50 mM Tris-HCl, pH 8.0, 
150 mM NaCl, 1 mM EDTA-NaOH, pH 8.0, 1 
mM DTT was digested with 0.25 μg of Genenase I 
for 3 h 30 m at 23 ºC (the results of these analyses 
are presented in Fig. S3 and Fig. S4). 
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Mass spectrometry analyses – Mass spectra were 
acquired in a MALDI mass spectrometer (4800 
Plus MALDI TOF/TOD Analyzer, SCIEX) using 
the 4000 Series Explorer v3.7.0 (build 1) SCIEX 
software, at i3S Proteomics Core Facility 
(Portugal). For peptide molecular mass 
determination, samples were diluted 10-fold in 10 
mg/mL of α-Cyano-4-hydroxycinnamic acid (50% 
ACN, 0.1% TFA) and 1 μL was spotted in a 
MALDI sample plate and allowed to dry. Spectra 
were acquired in reflector positive mode for the 
mass range m/z 1000 – m/z 3000 with and without 
internal standards (Angiotensin I, DRVYIHPFHL, 
m/z 1296.68), ACTH 1-17, 
SYSMEHFRWGKPVGKKR, m/z 2093.09, and 
ACTH 18–39, 
RPVKVYPNGAEDESAEAFPLEF, m/z 2465.20). 
For protein molecular mass determination, 
samples were diluted 10-fold in 10 mg/mL of 
sinapic acid matrix (50% ACN, 0.1% TFA), and 1 
μL was spotted in the MALDI sample plate and 
allowed to dry. Mass spectra were acquired in 
linear positive mode for the mass window m/z 
15000 – m/z 35000.  Mass spectra were internally 
calibrated with horse apomyoglobin, m/z 16952. 
For determination of protein cleavage location, 
data analysis was performed with the Findpept 
software ((84); http://web.expasy.org/findpept/). 
The maximum allowed error was 10 ppm for 
peptide masses. 
 
Density gradient centrifugation – A PK-treated 
PNS-based in vitro reaction (4.8 mg of PNS 
protein) was diluted with SEM buffer (0.25 M 
sucrose, 20 mM MOPS-KOH, pH 7.2, 1 mM 
EDTA-NaOH, pH 8.0) to 1.6 mL, and loaded onto 
the top of a Histodenz™ step gradient comprising 
1.5 mL of 45% (w/v), 5.5 mL of 28% (w/v), and 1 
mL of 20% (w/v) Histodenz™ in 5 mM MOPS-
KOH, pH 7.2, 1 mM EDTA-NaOH, pH 8.0. The 
gradient was centrifuged at 82500 g for 3 h at 4 
o
C 
in a 70.1 Ti rotor (Beckman), and 12 fractions 
were collected from the bottom of the gradient. 
After precipitation of proteins with 10% (w/v) 
trichloroacetic acid, ¼ of each fraction was 
analyzed by SDS-PAGE/western-
blotting/autoradiography. 
 
Antibodies – Antibodies directed to catalase (RDI-
CATALASEabr, Research Diagnostics, Inc.), 
KDEL (ab12223, Abcam), cytochrome c (556433, 
BD Pharmingen
TM
), Sterol Carrier Protein x 
(SCPx; 19182-1-AP, ProteinTech
TM
), and Tetra-
his (34670, Qiagen) were purchased. The antibody 
directed to PEX14 was described before (13). The 
antibody directed to PEX13 was produced in 
rabbits using recombinant histidine-tagged 
PEX13(236-403)(SH3) (51) by AMS 
Biotechnology. Antibodies were detected using 
goat alkaline phosphatase-conjugated anti-rabbit 
or anti-mouse antibodies (A9919 and A2429, 
respectively, Sigma). 
 
Miscellaneous – 35S-labeled proteins were 
synthesized using the TNTT7 quick coupled 
transcription/translation kit (Promega) as per 
manufacturer’s instructions, in the presence of 35S-
methionine (specific activity of >1000 Ci/mmol; 
PerkinElmer Life Sciences). Unless otherwise 
noted, 
35
S-labeled proteins were expressed as N-
terminally histidine-tagged fusion proteins from 
pET-28-derived plasmids. Syntheses yields from 
these plasmids were significantly larger than those 
obtained with pGEM-4-derived plasmids, used in 
previous works. For radiolabeled PEX5(C11A), a 
semi-quantitative western-blot analysis using the 
recombinant protein as a standard and the Tetra-
his antibody revealed yields of about 20 ng/µL of 
RRL. Yields were 2-3 fold larger for PEX5(1-
197;C11A/K) and PEX5(1-324;C11A/K), as 
assessed by quantitative autoradiography using 
radiolabeled PEX5(C11A) as a standard. 
Endogenous rat liver PEX5 was detected in 
western-blots by blot-overlay using radiolabeled 
PEX14, as described before (59). Sonication and 
fractionation of organelles was done exactly as 
described (27). Autoradiography data stored on 
phosphor screens were captured using a Storm 860 
Phosphorimager (GE, Amersham). Digital images 
were analyzed using the ImageQuant® version 5.0 
software (Molecular Dynamics). Peak fitting of 
densitometric profiles was done using Fityk – 
curve fitting and data analysis software (85). To 
estimate ratios of binding sites at saturation for 
PEX5(1-324;C11A):PEX5(C11A) and PEX5(1-
197;C11A):PEX5(C11A), data from four technical 
replicates were fitted to a dose response one-site 
specific binding curve equation, y = Bmax * x / 
(EC50 + x), using Prism® version 7.03 software 
(GraphPad software). In this equation y is the 
methionine- and PNS protein-normalized 
autoradiography signal of PK-resistant protein 
11
 at U
N
IV
ERSID
A
D
E D
O
 PO
RTO
 on N
ovem
ber 2, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
The peroxisomal matrix protein translocon 
bands, x is the volume of RRL containing the 
radiolabeled protein, Bmax is the maximal 
response at infinite volume of RRL, and EC50 is 
the volume of RRL yielding a half-maximal 
response. Note that since the actual concentrations 
of radiolabeled proteins in the RRL are not known, 
the absolute EC50 and Bmax values have no 
meaning per se. However, Bmax ratios provide the 
relative binding stoichiometries of the different 
PEX5 species. 
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FOOTNOTES 
The abbreviations used are: DTM, docking/translocation module; NDPEX14, protein comprising the first 
80 amino acid residues of PEX14; PIM, peroxisomal matrix protein import machinery; PK, proteinase K; 
PNS, post-nuclear supernatant; PTS, peroxisomal targeting signals; PTS1, PTS type 1; PTS2, PTS type 2; 
REM, receptor export module; RRL, rabbit reticulocyte lysate; TPRs, protein comprising amino acids 
residues 315-639 of PEX5; Ub-PEX5, monoubiquitinated PEX5. 
 
FIGURE LEGENDS 
 
FIGURE 1. PEX5 molecules used in this study. Full-length and truncated versions of the large isoform 
of human PEX5 are schematically represented. The conserved cysteine residue at position 11 (black), 
which was replaced by an alanine or a lysine in many of the proteins used in this work, the eight 
pentapeptide motifs responsible for the interaction with PEX13 and PEX14 (numbered from 0 to 7, dark 
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gray) and the structured C-terminal half comprising seven tetratricopeptide repeats (TPRs, light gray) are 
indicated. 
 
FIGURE 2. The PEX5-PEX14 interaction is resistant to alkaline pH. A, recombinant NDPEX14 (lane 
1), PEX5 (lane 3), and a mixture of both proteins (lane 2), were subjected to PAGE under alkaline 
conditions (50 mM phosphate buffer, pH 11.5), blotted onto a nitrocellulose membrane and stained with 
Ponceau S (left panel). Bands marked “a” to “c” were excised from the membrane and the proteins were 
eluted with Laemmli sample buffer and analyzed by SDS-PAGE/Coomassie blue staining (right panel). 
B, recombinant PEX5 (top panel), NDPEX14 (middle panel), and a mixture of both proteins (bottom 
panel), were subjected to SEC under alkaline conditions (0.12 M sodium carbonate). The void volume of 
the column was in fraction 14. Fractions were collected and analyzed by SDS-PAGE/Coomassie blue 
staining. In A and B, numbers to the left indicate the molecular weight (kDa) of protein standards. 
 
FIGURE 3. The DTM can accommodate more PEX5(1-197;C11A) molecules than full-length 
PEX5(C11A). A, Increasing volumes of rabbit reticulocyte lysates (RRL; volumes in μL indicated at the 
top of each lane) containing either PEX5(1-324;C11A) or PEX5(C11A) were used in PNS-based in vitro 
reactions (“rx”) performed in the presence of ATP for 45 min. Organelle suspensions were then treated 
with PK and analyzed by SDS-PAGE/phosphor imaging. Total organelle samples (PEX5(1-324;C11A)) 
or one third of them (PEX5(C11A)) were loaded onto the gel. The phosphor image (upper panel), and a 
section of the corresponding Coomassie blue-stained gel (middle panel) are shown. Numbers to the left 
indicate the molecular weight (kDa) of protein standards. Lower panel, data from the phosphor imaging 
quantitation were normalized for protein loads and methionine number in each radiolabeled protein (see 
Fig. S1 for details), fitted to a dose response one-site specific binding curve, and divided by the Bmax 
value obtained for full-length PEX5(C11A). Thus, values in the ordinate represent molar ratios of 
PEX5(1-324;C11A) to PEX5(C11A) (averages and standard deviations from four replicates are shown). 
Bmax for PEX5(1-324;C11A) and PEX5(C11A) are 1.21 (95% confidence interval (CI) = 0.88-1.99) and 
1.00 (95% CI = 0.85-1.18), respectively. Note that the abscissa scale is different for the two radiolabeled 
proteins. B, exactly as in A but using radiolabeled PEX5(1-197;C11A) and PEX5(C11A). Bmax for 
PEX5(1-197;C11A) and PEX5(C11A) are 2.52 (95% CI = 1.82-4.46) and 1.00 (95% CI = 0.90-1.11), 
respectively. In A and B, lanes In, RRL containing the indicated 
35
S-labeled proteins. Brackets and arrow 
heads indicate the PK-cleaved and intact PK-resistant
 35
S-labeled proteins, respectively. Note that intact 
PEX5(1-324;C11A) and intact PEX5(1-197;C11A) data cannot be fitted to the same dose response curve 
(“ambiguous fit”); in these cases the lines simply connect averages. Note also that for some points the 
error bars are shorter than the height of the symbols. 
 
FIGURE 4. Characterization of protease-protected PEX5(1-197;C11A) – part I. A, RRL containing 
PEX5(1-197;C11A) (lanes 1 and 2) or PK-treated organelles (Org.) from an in vitro assay programmed 
with PEX5(1-197;C11A) (lanes 3 and 4) were incubated or not with Genenase I (G I) for 30 min at 23 
o
C, 
as indicated. Samples were analyzed by SDS-PAGE/western-blotting/autoradiography. Autoradiograph 
(upper panel) and the corresponding Ponceau S-stained membrane (lower panel) are shown. B, A PK-
treated in vitro reaction performed with PEX5(1-197;C11A) was loaded onto the top of a Histodenz 
gradient and centrifuged. Twelve fractions were then collected from the bottom of the gradient and 
analyzed by SDS-PAGE/western-blotting/autoradiography. An autoradiograph (upper panel) showing the 
distribution of PK-resistant 
35
S-PEX5(1-197;C11A) species, and western-blots probed with antibodies 
directed to PEX14 (peroxisomes), cytochrome c (cyt c; mitochondria) and the retention signal KDEL 
(endoplasmic reticulum) are presented. Note that PEX14 is converted into a small fragment upon PK 
digestion (59). C, PK-treated organelles from an in vitro assay programmed with radiolabeled PEX5(1-
197;C11A) were disrupted by sonication. Half of the sample was kept on ice (lane T), and the other was 
centrifuged to separate membrane (lane P) and soluble (lane S) fractions. Samples were analyzed by SDS-
PAGE/western-blotting/autoradiography. The autoradiograph (upper panel) and blots showing the 
distribution of catalase (a peroxisomal matrix protein) and PEX14 (an intrinsic membrane protein) are 
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presented. D, Radiolabeled PEX5(1-197;C11A) was subjected to PNS-based in vitro assay in the absence 
(lane 1) or presence (lane 2) of 10 µM NDPEX14. PK-treated organelles were analyzed by SDS-
PAGE/autoradiography. The autoradiograph (upper panel) and the corresponding Ponceau S-stained 
membrane (lower panel) are shown. In C and D, lanes In, RRL containing 
35
S-labeled PEX5(1-
197;C11A). A to D, brackets and arrow heads indicate the PK-cleaved and PK-resistant intact
 35
S-labeled 
proteins, respectively. Numbers to the left indicate the molecular weight (kDa) of protein standards. 
 
FIGURE 5. Characterization of protease-protected PEX5(1-197;C11A) – part II. A, PNS-based in 
vitro assays showing that PEX5(1-197;C11A) competes with PEX5(C11A), and vice versa. PNS in 
import buffer containing ATP was pre-incubated for 5 min at 37 ºC in the absence or presence of the 
indicated recombinant proteins (15 μg of PEX5(1-197;C11A), or PEX5(C11A) or TPRs). Radiolabeled 
PEX5(1-197;C11A) and PEX5(C11A) were then added, as specified, and the reactions were incubated for 
30 min. PK-treated organelles were then subjected to SDS-PAGE/western-blotting/autoradiography. The 
autoradiograph (upper panel) and a portion of the Ponceau S-stained membrane (lower panel) are shown. 
Lanes In, RRL containing radiolabeled PEX5(1-197;C11A) and PEX5(C11A), as indicated. Stage 2 
PEX5(1-197;C11A) (bracket) and PK-resistant intact PEX5(1-197;C11A) (arrow head) are also indicated. 
B, PEX5(1-197;C11A) lacking a N-terminal histidine tag also yields PK-resistant intact species in in vitro 
assays. RRL (16 μL) containing radiolabeled untagged PEX5(1-197;C11A) was used in a PNS-based in 
vitro assay. The reaction was divided into two halves (lanes 3 and 4) and one half was treated with PK, as 
indicated. For comparison, an identical assay performed with histidine-tagged PEX5(1-197;C11A) (lanes 
1 and 2) is also shown. Organelle pellets were then subjected to SDS-PAGE/western-
blotting/autoradiography. The autoradiograph (upper panel) and a portion of the Ponceau S-stained 
membrane (lower panel) are shown. Lanes In, RRL containing histidine-tagged or untagged PEX5(1-
197;C11A). In A and B numbers to the left indicate the molecular weight (kDa) of protein standards. C, 
Radiolabeled PEX5(1-197;C11A) was incubated with a PNS in import buffer containing ATP. At the 
indicated time points, aliquots were withdrawn, treated with PK and the organelles were analyzed by 
SDS-PAGE/phosphor imaging. The brackets and arrow heads indicate stage 2 and PK-resistant intact 
PEX5(1-197;C11A), respectively. A densitometry profile of each lane is also shown. 
 
FIGURE 6. DTM-bound PEX5(1-125;C11K/A) is accessible to PK. A, PEX5(1-125;C11K) is 
correctly monoubiquitinated but does not acquire a PK-protected status. A primed PNS (see 
“Experimental Procedures”) was used in AMP-PNP-supplemented in vitro assays programmed with 
radiolabeled PEX5(1-197;C11K) (lanes 1 and 2; “C11K”), or PEX5(1-197;C11A) (lanes 3 and 4; 
“C11A”), or PEX5(1-125;C11K) (lanes 5 and 6; “C11K”), or PEX5(1-125;C11A) (lanes 7 and 8; 
“C11A”). One half of each reaction was treated with PK, as indicated. Organelle fractions were analyzed 
by SDS-PAGE/western-blotting/autoradiography. The autoradiograph (upper panel) and the 
corresponding nitrocellulose membrane probed with an antibody directed to Sterol Carrier Protein x 
(SCPx; lower panel), to assess intactness of peroxisomes (86), are shown. The exposure time of the 
PEX5(1-125;C11K/A) panel was 4-fold larger than the one of PEX5(1-197;C11K/A) to obtain similar 
intensities of the ubiquitinated species. Note that PEX5(1-197;C11K/A) and PEX5(1-125;C11K/A) have 
the same number of methionines.  Lanes InK and InA, RRL containing the C11K and C11A versions of the 
indicated 
35
S-proteins, respectively. B, Ub-PEX5(1-125;C11K), but not PEX5(1-125;C11K), is tightly 
bound to organelles. Radiolabeled PEX5(1-125;C11K) was incubated with a primed PNS in AMP-PNP-
containing import buffer for 30 min at 37 
o
C. The organelles were then recovered by centrifugation, 
resuspended in import buffer and divided into three tubes. One tube was kept on ice (lane T), and the 
other two were incubated for 15 min at 37 
oC in the presence of 10 μg of either recombinant PEX5(1-324) 
or PEX19, as indicated. Organelles (P) and the corresponding supernatants (S) were separated by 
centrifugation and analyzed by SDS-PAGE/autoradiography. Lane In, RRL containing the radiolabeled 
protein. The autoradiograph (upper panel) and a portion of the corresponding Ponceau S-stained 
membrane (lower panel) are shown. C, Ub-PEX5(1-125;C11K) is a substrate for the REM. Radiolabeled 
PEX5(1-197;C11K) (left panels) or PEX5(1-125;C11K) (right panels) were incubated with a primed PNS 
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in import buffer supplemented with ubiquitin aldehyde and AMP-PNP. The reactions were then 
centrifuged to separate supernatant fraction (Si) from organelles (Pi). The organelles were resuspended in 
an ATP- or AMP-PNP-containing import buffer, and further incubated for 15 min at 37 
o
C. The organelle 
suspensions were again centrifuged to obtain a supernatant (Se) and an organelle pellet (Pe). Samples were 
analyzed by SDS-PAGE/western-blotting/autoradiography. The autoradiographs (upper panels) and the 
behavior of endogenous PEX13 (lower panels) are shown. Si, equivalent to 50 μg of PNS; Pi, Pe and Se, 
equivalent to 600 μg of PNS. Lanes In, RRL containing the radiolabeled protein. In B and C, a and b 
indicate monoubiquitinated and non-ubiquitinated PEX5 species, respectively. D, Radiolabeled PEX5(1-
125;C11K)-clv is partially processed in the PNS-based in vitro assay. Radiolabeled PEX5(1-125;C11K)-
clv and PEX5(1-125;C11K)-nclv were subjected to PNS-based in vitro assays in the presence of AMP-
PNP for 60 min. The reactions were then centrifuged to separate organelles (lanes P) from soluble 
proteins (lanes S). Organelles and soluble fractions from 600 and 100 μg of PNS, respectively, were 
subjected to SDS-PAGE/western-blotting/autoradiography. Lanes Inclv and Innclv, RRL containing the 
indicated 
35
S-labeled proteins. The autoradiograph (upper panel) and the corresponding Ponceau S-stained 
membrane (lower panel) are shown. The cleaved species is indicated by an arrow head. Numbers to the 
left indicate the molecular weight (kDa) of protein standards. 
 
FIGURE 7. Two non-overlapping PEX5 fragments interact with the DTM in a competitive manner. 
A, PNS-based in vitro assays were performed with radiolabeled PEX5(N137) in the presence of ATP 
and 1 µM of recombinant TPRs or TPRs(N526K). Note that N526K mutation abolishes the PTS1-binding 
activity of TPRs (87). PK-treated organelles were then analyzed by SDS-PAGE/western-
blotting/autoradiography. Lane In, RRL containing 
35
S-PEX5(N137). B, Radiolabeled PEX5(1-
197;C11K) or PEX5(1-125;C11K) were subjected to PNS-based in vitro assays in the presence of AMP-
PNP and in the absence or presence of 1 µM of recombinant TPRs or PEX5(N137), as indicated. 
Organelle fractions were analyzed by SDS-PAGE/western-blotting/autoradiography. The exposure time 
of the PEX5(1-125;C11K) panel was 4-fold larger than that of PEX5(1-197;C11K). Lanes In, RRL 
containing the indicated 
35
S-proteins. C, Radiolabeled PEX5(1-125;C11K) was incubated with a primed 
PNS in AMP-PNP-containing import buffer for 30 min. The organelles were then isolated by 
centrifugation, resuspended in import buffer and divided into three tubes. One tube remained on ice (lane 
T). The others were incubated for 15 min at 37 
o
C in the presence of 10 µg of either recombinant 
PEX5(N137) or TPRs, as indicated. Organelle (P) and soluble proteins (S) were separated by 
centrifugation and analyzed by SDS-PAGE/western-blotting/autoradiography. Lane In, RRL containing 
35
S-PEX5(1-125;C11K). In B and C, a and b indicate monoubiquitinated and non-ubiquitinated PEX5 
species, respectively. A to C, Autoradiographs (upper panels) and corresponding Ponceau S-stained 
membranes (lower panels) are shown. Numbers to the left indicate the molecular weight (kDa) of protein 
standards. 
 
FIGURE 8. Model of the peroxisomal matrix protein translocon (DTM). The docking/translocation 
module (DTM), comprising the transmembrane proteins PEX14, PEX13 and RING finger PEX2, PEX10 
and PEX12, is a large cavity-forming protein assembly into which soluble PEX5 enters to release its 
cargo. Each site at the DTM available to bind one full-length PEX5 molecule can accommodate one 
PEX5(1-324) molecule or 2-3 PEX5(1-197) molecules (thick arrows). The small PEX5(1-125) species 
also interacts correctly with DTM, albeit with low efficiency (dashed arrow); interestingly, it remains 
largely accessible to proteinase K added from the cytosolic side of the membrane. Furthermore, 
PEX5(N137) competes with PEX5(1-125) in the interaction with the DTM (red line), a finding 
suggesting that the DTM can recruit cytosolic PEX5 through different pentapeptide motifs. The putative 
disorder of DTM components (purple ovals with wavy lines) might contribute to this interaction 
flexibility. The C-shaped form and the thick blue line represent the PTS1-binding domain and the 
intrinsically disordered N-terminal half of PEX5, respectively. The black dots indicate the pentapeptide 
motifs involved in the interactions with PEX14 and PEX13. 
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The peroxisomal matrix protein translocon is a large cavity-forming protein assembly into which 
PEX5 protein enters to release its cargo. 
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Supplemental material includes: 
• Table S1. Oligonucleotides used in this study. 
• Figure S1. Determination of molar ratios of DTM-bound PEX5 molecules. 
• Figure S2. The amount of organelle-associated PK-protected endogenous PEX5 is highly 
decreased upon incubation at 37 ºC in the presence of ATP. 
• Figure S3. Mass spectrometry analyses of intact and Genenase I-cleaved recombinant PEX5(1-
197;C11A) in the reflectron positive mode. 
• Figure S4. Mass spectrometry analyses of intact and Genenase I-cleaved recombinant PEX5(1-
197;C11A) in the linear positive mode. 
• Figure S5. Control assay showing that the slower migrating radioactive bands detected in PNS-
based in vitro assays programmed with PEX5(1-125;C11K) and PEX5(1-197;C11K) upon SDS-
PAGE represent monoubiquitinated species. 
• References 
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TABLE S1. Oligonucleotides used in this study. 
 
Plasmid Sequence 5’ - 3’  
pET-28-PEX5 Fw:GCGAACTGCATATGGCAATGCGGGAGCTGG 
Rv:GCGTAATTAAGCTTGGCTGCAGGTC 
pET-28-PEX5(1-125;C11A) Fw:GATGCGTCATATGGCAATGCGGGAGCTGGT 
Rv:GATCGCAAGCTTTCAAGCTGCAAGAAACTCCTG 
pET-28-PEX5(1-197;C11A) Fw:CTCGATCCCGCGAAATTAATACGACTC 
Rv:CGCCAAGCTTTTACGTGTGCTGCAGATCCTCCTC 
pET-23-PEX5(∆N137) Fw:GGAACGCATATGACTGACTGGTCCCAAGAATTCATCTC 
Rv:GATAACGTCGACTCACTGGGGCAGGCCAAACATAG 
“for expression PCR”  
PEX5(1-197;C11A) 
Fw:GCCCAATACGCAAACCGCCTCTCC 
Rv:GATAATCACGTGTGCTGCAGATCCTCCTCAGG 
“TEV protease cleavage site” 
pET-28-TEV-PEX5(∆N137) 
Fw:[Phos]TATGGAGAACCTTTATTTCCAGGGCCA 
Rv:[Phos]TATGGCCCTGGAAATAAAGGTTCTCCA 
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FIGURE S1. Determination of molar ratios of DTM-bound PEX5 molecules. A, N-terminal sequence 
of the histidine-tagged PEX5 species used in this work. The conserved cysteine at position 11 is marked, 
as are all methionine residues (bold, underlined). The cleavage site of Genenase I (Gen. I ) and the 
approximate cleavage site of PK (PK ) that yields the smallest PK-protected stage 2 PEX5 species are 
also shown. Note that there is some uncertainty in defining the latter cleavage site. Thus, two possibilities 
are considered: PK cleaves after methionine 18 or PK cleaves before methionine 18. The number of 
methionine residues in both intact PEX5 and smallest PK-protected stage 2 PEX5 species are presented in 
the table on the right side. B-E, Quantitative analyses of autoradiography data. Densitometric analysis of 
radiolabeled proteins bands was performed with ImageQuant® software (B). For each selected gel area 
(red squares), a single volume value was determined that includes both intact and truncated PEX5 species. 
Quantitation was performed with a local median background correction. Values for 
35
S-PEX5(C11A) 
were multiplied by 3, as only 1/3 of the in vitro reactions were loaded onto the gels. To determine the 
contribution of each individual band, in PEX5(1-197;C11A) and PEX5(1-324;C11A) experiments, 
intensity profiles along intersecting red lines were plotted (C). The intensity profiles (D) were then 
deconvoluted using Fityk software (1) (E); the thin grey line represents the raw data obtained with 
ImageQuant®; the black line represents the assisted fitting of each peak (peaks I to V); the blue lines 
represent the deconvoluted peaks as determined by Fityk. F, molar ratios of DTM-bound truncated 
PEX5(C11A) species to full-length PEX5(C11A). Signal intensities for each of the resolved PEX5 
species (peaks I-V in E) were normalized for the number of methionine residues considering three 
different possibilities. In the first possibility (scenario #1) we assumed that: 1) the smallest PK-protected 
PEX5 species (peak I in E) has the same size, and therefore the same number of methionines, of Genenase 
I-cleaved PEX5 species (see Fig. 4A); 2) the largest PK-cleaved PEX5 species (peak IV in E) is larger 
than the corresponding untagged PEX5 species (see Fig. 5B); and 3) the difference in size between any 
two adjacent PK-resistant species in the SDS-gel is approximately 1 kDa (see Fig. 3). In the two other 
possibilities we just assumed that band/peak IV is larger than the untagged protein (see Fig. 5B) and that 
all the other PK-accessible species contain either the minimum (scenario #2) or the maximum number of 
possible methionines (scenario #3). Thus, these two possibilities yield the largest and smallest ratios of 
truncated PEX5 species to full-length PEX5, respectively. Graphical representation of scenarios #2 and 
#3 for PEX5(1-197;C11A):PEX5(C11A) and PEX5(1-324;C11A):PEX5(C11A) are presented (see main 
text for scenario #1). The data were fitted to a dose response one-site specific binding curve, and divided 
by the Bmax value obtained for full-length PEX5(C11A). Thus, values in the ordinate represent molar 
ratios of PEX5(1-324;C11A) or PEX5(1-197;C11A) to PEX5(C11A) (averages and standard deviations 
from four replicates are shown). In scenario #2, the Bmax for PEX5(1-197;C11A) and PEX5(C11A) are 
3.24 (95% CI = 2.32-5.87) and 1.00 (95% CI = 0.90-1.11), respectively (left panel); and the Bmax for 
PEX5(1-324;C11A) and PEX5(C11A) are 1.35 (95% CI = 0.97-2.28) and 1.00 (95% CI = 0.85-1.18), 
respectively (right panel). In scenario #3, the Bmax for PEX5(1-197;C11A) and PEX5(C11A) are 1.82 
(95% CI = 1.31-3.24) and 1.00 (95% CI = 0.90-1.11), respectively (left panel); and the Bmax for PEX5(1-
324;C11A) and PEX5(C11A) are 1.02 (95% CI = 0.75-1.69) and 1.00 (95% CI = 0.85-1.18), respectively 
(right panel). Note that the abscissa scale is different for the two radiolabeled proteins. Note that intact 
PEX5(1-324;C11A) and intact PEX5(1-197;C11A) data cannot be fitted to the same dose response curve 
(“ambiguous fit”); in these cases the lines simply connect averages. Note also that for some points the 
error bars are shorter than the height of the symbols. 
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FIGURE S2. The amount of organelle-associated PK-protected endogenous PEX5 is largely 
decreased upon incubation at 37 ºC in the presence of ATP. A rat liver PNS in ATP-containing import 
buffer was incubated at 0 or 37 ºC in the absence (lanes 1, 2 and 4) or presence (lane 3) of 10 µM 
recombinant NDPEX14. After incubation, samples were treated (+) or not (–) with PK, as indicated. 
Organelles were then isolated and subjected to reducing SDS-PAGE/western-blotting. Endogenous rat 
PEX5 was detected by blot-overlay using 
35
S-PEX14. Stage 2 and stage 3, DTM-embedded non-
ubiquitinated and monoubiquitinated PEX5 species, respectively. Note that the Ub-PEX5 thioester 
conjugate is destroyed under reducing conditions. Thus, only the full-length PEX5 protein is detected in 
reducing gels (2). The autoradiograph (upper panel) and the corresponding Ponceau S-stained membrane 
(lower panel) are shown. Numbers to the left indicate the molecular weight (kDa) of protein standards. 
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FIGURE S3. Mass spectrometry analyses of intact and Genenase I-cleaved recombinant PEX5(1-
197;C11A) in the reflectron positive mode. Genenase I cleaves particularly well at sites having a 
histidine at the P2 position and a phenylalanine or a tyrosine at the P1 position (3).  Although there are 
two such sequences in human PEX5 (His23Phe24 and His578Phe579) previous work suggests that only 
the first of these sites is cleaved by Genenase I (4). To determine whether Genenase I cleaves PEX5(1-
197;C11A) at the first of these sites (corresponding to residues His43Phe44 in the histidine-tagged 
PEX5(1-197;C11A) protein) the intact and Genenase I-digested proteins were analyzed by mass 
spectrometry. No peptides were found in the undigested protein (A) whereas five major peptides were 
detected in the Genenase I-cleaved protein (B). The five peptides map to the 1- 44 amino acid region of 
recombinant PEX5(1-197;C11A), as determined by the FindPept program (5) using the “unspecific 
cleavage” option and a mass tolerance of 10 ppm (C). In B, arrows indicate the internal standards added 
to the sample. 
 
Supplemental data: The peroxisomal matrix protein translocon 
 
S-8 
 
 
 
 
 
Supplemental data: The peroxisomal matrix protein translocon 
 
S-9 
 
FIGURE S4. Mass spectrometry analyses of intact and Genenase I-cleaved recombinant PEX5(1-
197;C11A) in the linear positive mode. Masses of 23963.6 Da (MH+) for the undigested protein 
(theoretical mass 23961.172 Da (MH+), excluding the initial methionine) and 19405.6 Da for the 
Genenase I-cleaved protein were determined. This suggests that Genenase I removes a domain of 4576 
Da from recombinant PEX5(1-197;C11A), in good agreement with the theoretical molecular mass of 
4576.13 Da for a peptide comprising amino acid residues 2-44 of the protein. In A and B, the arrow 
indicates the internal mass standard horse myoglobin. 
 
 
 
FIGURE S5. Control assay showing that the slower migrating radioactive bands detected in PNS-
based in vitro assays programmed with PEX5(1-125;C11K) and PEX5(1-197;C11K) upon SDS-
PAGE represent monoubiquitinated species. Radiolabeled PEX5(1-125;C11K) or PEX5(1-197;C11K) 
were subjected to PNS-based in vitro assays in the presence of AMP-PNP and either ubiquitin (Ub; lanes 
1 and 3) or a glutathione S-transferase-ubiquitin fusion protein (GST-Ub; lanes 2 and 4). Organelles were 
isolated by centrifugation and analyzed by SDS-PAGE/autoradiography. The autoradiograph (upper 
panel) and a portion of the corresponding Ponceau S-stained membrane (lower panel) are shown. The 
exposure time of the PEX5(1-125;C11K) panel was 4-fold larger than the one of PEX5(1-197;C11K). 
Lanes In, RRL containing the radiolabeled proteins, as indicated. a and c, Ub-PEX5 and GST-Ub-PEX5 
species, respectively; b, non-ubiquitinated PEX5 species. Note that, in lanes 2 and 4, Ub-PEX5 species 
containing endogenous ubiquitin are also observed. Numbers to the left indicate the molecular weight 
(kDa) of protein standards. 
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